<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Exoskeleton</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>​Ottobock plans 2025 IPO on Frankfurt exchange</title>
      <description>
        <![CDATA[German bionics leader Ottobock SE & KGaA plans to list on the Frankfurt Stock Exchange by the end of the year in an IPO targeting gross proceeds of €100 million (US$117.7 million). Ottobock would be the fourth European company to go public this year, a good sign for the European med-tech market, which had not seen any since the first half of 2022.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724091</guid>
      <pubDate>Mon, 15 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724091-ottobock-plans-2025-ipo-on-frankfurt-exchange</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Businessman-and-IPO-virtual-screen.webp?t=1717791671" type="image/jpeg" medium="image" fileSize="332138">
        <media:title type="plain">Businessman and IPO virtual screen</media:title>
      </media:content>
    </item>
    <item>
      <title>Reev secures $9.2M for lightweight exoskeleton</title>
      <description>
        <![CDATA[Reev SAS raised $9.2 million in a financing round that will fund further development of its lightweight exoskeleton Dreeven.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716845</guid>
      <pubDate>Fri, 07 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716845-reev-secures-92m-for-lightweight-exoskeleton</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Reev-Dreeven-exoskeleton-7feb25.webp?t=1738969020" type="image/jpeg" medium="image" fileSize="429802">
        <media:title type="plain">Reev Dreeven exoskeleton</media:title>
        <media:description type="plain">Reev Dreeven exoskeleton. Credit: Reev</media:description>
      </media:content>
    </item>
    <item>
      <title>Ekso steps up with FDA clearance for exoskeleton use in MS</title>
      <description>
        <![CDATA[Ekso Bionics Holdings Inc. added a new indication for its robotic Eksonr exoskeleton with a U.S. FDA 510(k) clearance for use of the mobility device in patients with multiple sclerosis (MS). The green light for MS follows clearances for stroke and spinal cord rehabilitation in 2016 and acquired brain injury (ABI) in 2020.]]>
      </description>
      <guid>http://www.bioworld.com/articles/519765</guid>
      <pubDate>Tue, 14 Jun 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/519765-ekso-steps-up-with-fda-clearance-for-exoskeleton-use-in-ms</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/06-14-Ekso-Bionics-Eksonr.webp?t=1655242602" type="image/png" medium="image" fileSize="802056">
        <media:title type="plain">Person using Eksonr</media:title>
        <media:description type="plain">Ekso Bionics’ Eksonr exoskeleton.</media:description>
      </media:content>
    </item>
    <item>
      <title>Able sets in motion plan to launch low-cost robotic exoskeleton</title>
      <description>
        <![CDATA[The rehabilitation robot market will soon have a new entrant as Able Human Motion SL prepares to launch a next-generation robotic exoskeleton. The Universitat Politècnica de Catalunya spin-off is on a mission to shake up the exoskeleton technology market with a low-cost, lightweight model that can be accessed by anyone with mobility impairments.]]>
      </description>
      <guid>http://www.bioworld.com/articles/518251</guid>
      <pubDate>Tue, 26 Apr 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/518251-able-sets-in-motion-plan-to-launch-low-cost-robotic-exoskeleton</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/04-26-Able-Exoskeleton.webp?t=1651008872" type="image/png" medium="image" fileSize="1295488">
        <media:title type="plain">Woman wearing Able exoskeleton walking outside</media:title>
        <media:description type="plain">The Able robotic exoskeleton is low cost and lightweight. Credit: Able Human Motion SL.</media:description>
      </media:content>
    </item>
    <item>
      <title>Wandercraft lines up $45M for exoskeleton technology</title>
      <description>
        <![CDATA[Exoskeleton company Wandercraft SAS has landed $45 million in a series C round led by U.S. fund Quadrant Management. The company’s first commercial exoskeleton, Atalante, received CE marking in 2019 and has sold for around $176,000 a piece to European rehabilitation hospitals offering gait re-learning treatment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/515350</guid>
      <pubDate>Fri, 21 Jan 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/515350-wandercraft-lines-up-45m-for-exoskeleton-technology</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/financings-international-foreign-currency.webp?t=1751908080" type="image/png" medium="image" fileSize="509882">
        <media:title type="plain">International currency symbols</media:title>
      </media:content>
    </item>
    <item>
      <title>Stoko raises C$6M seed round to market K1 knee brace</title>
      <description>
        <![CDATA[TORONTO &ndash; Startup company Stoko Inc. has raised C$6 million (US$4.74 million) in seed funding to accelerate market expansion of a device it said will give rigid knee braces a run for their money.]]>
      </description>
      <guid>http://www.bioworld.com/articles/507338</guid>
      <pubDate>Thu, 20 May 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507338-stoko-raises-c6m-seed-round-to-market-k1-knee-brace</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/05-20-Stoko-k1-embrace.webp?t=1621546282" type="image/png" medium="image" fileSize="1555893">
        <media:title type="plain">Woman wearing K1 Embrace runs up set of stairs</media:title>
        <media:description type="plain">K1 Embrace knee support tight. Credit: Stoko Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Neurolutions wins de novo nod for stroke rehabilitation device</title>
      <description>
        <![CDATA[The FDA has granted de novo authorization to Neurolutions Inc. for its Ipsihand upper extremity rehabilitation system. The first-of-its kind device leverages robotics and brain-computer interface (BCI) technology to facilitate muscle training in patients with upper limb weakness or immobility following a stroke.]]>
      </description>
      <guid>http://www.bioworld.com/articles/506364</guid>
      <pubDate>Mon, 26 Apr 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/506364-neurolutions-wins-de-novo-nod-for-stroke-rehabilitation-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/04-26-Neurolutions-Ipsihand.webp?t=1619473718" type="image/png" medium="image" fileSize="1385731">
        <media:title type="plain">Patient wearing Ipsihand</media:title>
        <media:description type="plain">Ipsihand upper extremity rehabilitation system. Credit: Neurolutions Inc. </media:description>
      </media:content>
    </item>
    <item>
      <title>Exonet gives patients a leg up with autonomous, motor-controlled tech</title>
      <description>
        <![CDATA[TORONTO &ndash; Robotics researchers at Ontario&rsquo;s University of Waterloo are stealing a page from makers of autonomous or self-driving vehicles, developing wearable, motor-controlled technology to restore physical mobility in people with disabilities without the need to think about or guide the system. The project, called Exonet, is being led by Brokoslaw Laschowski, who contrasts this approach with engineers ramping up the ability of users to control the exoskeleton.]]>
      </description>
      <guid>http://www.bioworld.com/articles/505497</guid>
      <pubDate>Fri, 02 Apr 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/505497-exonet-gives-patients-a-leg-up-with-autonomous-motor-controlled-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/04-02-Exonet.webp?t=1617383287" type="image/png" medium="image" fileSize="1460647">
        <media:title type="plain">Brokoslaw Laschowski wearing exoskeleton in front of a stairway</media:title>
        <media:description type="plain">Exonet project lead Brokoslaw Laschowski demonstrates how autonomous, motor control technologies will help people with disabilities conquer their most challenging task: climbing stairs.</media:description>
      </media:content>
    </item>
    <item>
      <title>B-Temia gains traction with 510(k) clearance for mobility device</title>
      <description>
        <![CDATA[B-Temia Inc.&rsquo;s Keeogo mobility device is on the move in the U.S. now that it has received 510(k) clearance from the U.S. FDA. Unlike currently available exoskeletons that move for patients, the Keeogo (keep on going) Dermoskeleton system amplifies signals from patients who can initiate movement but need additional assistance.]]>
      </description>
      <guid>http://www.bioworld.com/articles/497746</guid>
      <pubDate>Mon, 14 Sep 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/497746-b-temia-gains-traction-with-510k-clearance-for-mobility-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/9-14-B-Temia-Keeogo.webp?t=1600119867" type="image/png" medium="image" fileSize="677780">
        <media:title type="plain">Man wearing Keeogo about to climb stairs</media:title>
        <media:description type="plain">Keeogo provides stability and strength to stroke patients with limited mobility. Credit: B-Temia Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Ekso's robotic exoskeleton gets FDA nod for use with ABI patients</title>
      <description>
        <![CDATA[Ekso Bionics Holdings Inc. has received a green light from the U.S. FDA to market its Eksonr robotic exoskeleton for use with patients with acquired brain injury (ABI). The company said it is the first exoskeleton product to receive the agency&#39;s nod for rehabilitation use with ABI, allowing a broader patient population to access the device. This is good news for Richmond, Calif.-based Ekso, which, like many other device companies, saw its earnings off during the first quarter. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/436066</guid>
      <pubDate>Thu, 25 Jun 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/436066-eksos-robotic-exoskeleton-gets-fda-nod-for-use-with-abi-patients</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/6-24-Ekso-Bionics-EksoNR.webp?t=1593124165" type="image/png" medium="image" fileSize="639713">
        <media:title type="plain">Man wearing Eksonr during therapy</media:title>
        <media:description type="plain">Eksonr robotic exoskeleton. Credit: Ekso Bionics Holdings Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Rewalk Robotics sees impact of COVID-19 in first-quarter results</title>
      <description>
        <![CDATA[Like many companies, Rewalk Robotics Ltd. saw its financials hit by the COVID-19 pandemic. It revealed May 28 that its total revenue for its first quarter fell to $0.8 million, down from $1.6 million during the same period last year. The company, which focuses on solutions that give gait training and mobility for individuals with lower limb disabilities, acknowledged the effects of the pandemic, noting that several Rewalk Personal 6.0 devices were not delivered as a result.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435413</guid>
      <pubDate>Thu, 28 May 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435413-rewalk-robotics-sees-impact-of-covid-19-in-first-quarter-results</link>
    </item>
  </channel>
</rss>
